Search
+
    SEARCHED FOR:

    SUVEN PHARMACEUTICALS STOCK

    ​These 4 stocks closed crossing above VWAP on June 25
    Suven Pharma to acquire controlling stake in Hyderabad-based CDMO Sapala Organic

    Suven will initially acquire a 67.5% equity stake of Sapala subject to customary working capital and net debt adjustments, the remaining stake a few months after FY2026-27, as per the terms of the definitive agreements, the company told stock exchanges.

    Fundamental tailwinds are a stronger play than volatile markets? 5 Indian pharma stocks with upside potential of up to 31 %

    There is no doubt that the market is going through a volatile phase and bears are once again telling the street to never write them off. Will this correction continue even longer ? It would probably be clear by the end of the day as the election result finally gets settled. Instead of focusing on how much nifty or bank nifty or any other index is down or up, focus on the fact that whether the sector or company is doing well and will it do well in future because the fundamental operating matrix of that sector has changed for better. Because volatile phases come and go, changes in the operating matrix don't happen every day. Pharmaceutical is one sector where there is a fundamental change taking place and it has happened after 8 to 10 years of restructuring and painful readjustment. So, it would be worthwhile to have them on watchlist and if the market remains volatile then it is a sector which probably has a higher probability of outperforming.

    Corrections are opportunities for long term investors: 5 midcaps with right mix and upside potential of up to 46%

    For the next couple of weeks, what will dominate the narrative on the street would be the action and expectation from the US Fed and Iran’s attack on Israel and whether it escalates further or not. At a time when events where no one has any control are hitting the street, two things are most important, first, don't react in panic. Now panic is not only about selling because the news is negative, but also about buying just because stock prices have fallen from its recent high. It is time to remember that there is not even a single year in the last 25 years, when there has not been an issue which made it appear that the world is going to crumble. But the fact is good businesses have still grown, valuations have still risen and broader markets have moved higher. So, these geopolitical tensions are part of life only if one focuses on what one is investing into and puts more checks and balances so that one is able to bring in the element of margins of safety.

    These 4 stocks closed crossing above VWAP on March 28
    Turnaround story: 40 smallcaps that lost over 30% in FY23, turn multibaggers in FY24

    The FY24 has been a turnaround year for smallcap stocks, witnessing a significant rally with many stocks turning multibaggers. However, concerns over valuations raised by Sebi might moderate returns in FY25. While equity bulls partied hard in most of FY24, the Securities and Exchange Board India (Sebi) turned a party spoiler towards the end.

    • Fundamental tailwinds are a stronger play than volatile markets? 5 Indian pharma stocks with upside potential of up to 41%

      There is no doubt that the market is going through a volatile phase and bears are once again telling the street to never write them off. Will this correction continue even longer ? The probability is high. But then every few months there is a phase of volatility which comes to market and stocks and sector corrects. Some more, some less. Instead of focusing on how much nifty or bank nifty or any other index is down or up, focus on the fact that whether the sector or company is doing well and will it do well in future because the fundamental operating matrix of that sector has changed for better. Because volatile phases come and go, changes in the operating matrix don't happen every day. Pharmaceutical is one sector where there is a fundamental change taking place and it has happened after 8 to 10 years of restructuring and painful readjustment. So, it would be worthwhile to have them on watchlist.

      Merger effect! Suven Pharma shares jump 15% in 2 days

      After the merger becomes effective, all shareholders of Cohance will be issued shares of Suven at the ratio of 11 shares of Suven for every 295 shares of Cohance, based on the swap ratio. The new shares of Suven will be traded on the NSE and BSE.

      Suven Pharmaceuticals shares soar 13% on proposed merger with Cohance Lifesciences

      Shares of Suven Pharmaceuticals surged 13% on the NSE after proposing a merger with Cohance Lifesciences to strengthen its CDMO industry position. After the merger, Advent entities will own 66.7%, and the transaction is expected to conclude in 12-15 months.

      JSW Steel shares jump 4%, market cap crosses Rs 2 lakh crore mark. Here’s why

      JSW Steel's shares rose 4.4% as it incorporated JSW Green Steel Ltd for steel product manufacturing. Its market cap surpassed Rs 2 lakh crore, making it the top Nifty gainer. The stock has delivered nearly 23% in the last 12 months, underperforming Nifty50.

      Share market update: Most active stocks of the day in terms of total traded value

      The NSE Nifty index was trading 196.86 points up at 22179.65

      Stocks in news: Suven Pharma, MOIL, Adani stocks, ICICI Lombard, Vedanta

      Suven Pharmaceuticals and Cohance Lifesciences signed a definitive agreement to merge their businesses, which will further strengthen the former’s position in contract development and manufacturing organization (CDMO) space.

      These 26 companies saw over 25% drop in Q3 sales, PAT; are they still worth betting on?

      Around 26 companies, with a market capitalisation of over Rs 2,500 crore, reported atleast 25% year-on-year (YoY) fall in both revenue and profits in the last quarter, and a majority of them were part of the chemicals and pesticides sector.

      Route Mobile, MRF among five stocks with falling RSI trends

      Keeping tabs on the Relative Strength Index (RSI) can reveal much about a stock's potential movement. On November 3, Friday, StockEdge detected 14 stocks with RSI trending down. In this article, we zoom in on 5 of these stocks to understand the significance of RSI and how it can guide investment decisions.

      Phoenix Mills, Bharti Airtel among 6 stocks with bearish RSI trends

      ETMarkets examines the intriguing combination of overbought stocks with declining RSI trends and highlights 6 stocks for investors to watch closely.

      Tata Investment, 3 other stocks trading with bearish RSI

      Discover the art of decoding stock movements as we unveil 10 stocks trading in the overbought zone with declining Relative Strength Index (RSI) trends. ETMarkets explores the significance of RSI and its role in making informed investment decisions.

      Suven Pharmaceuticals shares jump over 6% after cabinet approves Rs 9,589 crore FDI

      According to the latest shareholding pattern available with the exchanges, as of 30 June 2023, 60% of the company's shareholding is with the promoter & promoter group, and 40% with the public.

      Cabinet approves foreign investment of up to Rs 9,589 crore in Suven Pharma

      The Cabinet Committee on Economic Affairs has approved foreign investment of up to Rs 9,589 crore in Suven Pharmaceuticals by Cyprus-based Berhyanda Limited. This Cabinet approval allows Berhyanda to acquire up to 76.1% equity shares of Suven Pharmaceuticals, potentially increasing the aggregate foreign investment in the company up to 90.1%.

      Finally out of the woods? 5 small and midcap pharma stocks with an upside potential of up to 23%

      Pharma as a sector, both in terms of business and stocks price performance has been under pressure for a very long time. Some time USFDA issues, at other instances of pricing pressure in US markets have been troubling the sector. However, recently some tailwinds have emerged both for the companies focussing on domestic pharma and also the ones focussed on the US generic market. The list is based on upside estimated by the analysts, with the highest potential stock coming on the top of the list.

      PVR Inox, REC among 10 overbought stocks with RSI above 70

      As of August 18, Friday, ETMarkets identified the overbought status of the chosen stocks. Given the dynamic nature of markets, remember that market conditions can change rapidly. The status of stocks trading in an overbought zone on August 21, Monday, will be updated after market hours.

      Cochin Shipyard, REC among 10 overbought stocks with RSI above 70

      In the intricate world of stock trading, decoding the dynamics of Relative Strength Index (RSI) trends is crucial. On August 17, StockEdge spotlighted a captivating situation where 50 stocks found themselves in the overbought territory while displaying bearish or declining RSI trends.

      Lupin, Kalyan Jewellers among 10 overbought stocks with RSI above 70

      This article sheds light on the concept of RSI and its significance in assessing stock movements, with a focus on ten stocks that have entered the overbought zone. As data from StockEdge revealed over 50 such stocks, and ETMarkets selected 10, we delve into why RSI matters and how it can empower investors to make informed choices.

      Adani Ports, Zomato among 10 stocks with bearish RSI

      The intricacies of stock trading require astute decision-making. One critical tool in this endeavor is the Relative Strength Index (RSI), which helps assess stock trends. This article delves into RSI's importance, its role in evaluating stocks, and investigates 10 stocks in the overbought zone with bearish RSI trends.

      Auto, pharma stocks offering margin of safety top funds' buy list in July

      Shares in the pharma and automotive sectors were among those that fit the bill. Fund managers lapped up pharma given the recent underperformance, lower input prices and attractive valuations. With first-quarter results encouraging, they bought into stocks like Dr Reddy's Laboratories, Aurobindo Pharma, and Suven Pharmaceuticals.

      For risk takers: 5 midcap stocks from different sectors with score improvement and potential upside of up to 31%

      While the nifty corrected last week, even then more mid caps stocks are joining the party. Stocks from sectors like construction, pharma fertilizer have come to the list. ET screener powered by Refinitiv’s Stock Report Plus applies different algorithms & filters to all BSE and NSE stocks, and lists stocks which fulfill the various criteria as specified into the algorithms & filters to find those which might help navigate the stock market.

      Adani Total Gas, JSW Energy among 10 stocks with RSI trending up

      On July 25, Tuesday, StockEdge reported 34 stocks showing an uptrend in the Relative Strength Index (RSI), indicating positive momentum

      Suven Pharmaceuticals, Sapphire Foods among 10 stocks with RSI trending up

      The Relative Strength Index (RSI) which measures a stock's price momentum, can help investors make informed decisions. ETMarkets has identified 10 stocks that are currently trading in an overbought zone as the RSI scales 0 to 100, values above 70 suggest overbought conditions. Some of the stocks with trending RSI included Suven Pharmaceuticals

      Finally out of the woods? 4 small and midcap pharma stocks with an upside potential of up to 26%

      Pharma as a sector has been under pressure for a very long time. Some time USFDA issues, at other instances of pricing pressure in US markets have been troubling the sector. However, some of the small and mid sized Indian pharma companies which are not hit by pricing pressure of the US generic market and other issues which large pharma companies have been facing keep attracting interest from the analyst. The list is based on upside estimated by the analysts, with the highest potential stock coming on the top of the list.

      On path to recovery: 4 small- and mid-cap pharma stocks with upside potential up to 27%

      Pharma as a sector has been under pressure for a very long time. However, some of the small and mid sized Indian pharma companies which are not hit by pricing pressure of the US generic market and other issues which large pharma companies have been facing keep attracting interest from the analyst. The list is based on upside estimated by the analysts, with the highest potential stock coming on the top of the list.

      Load More
    The Economic Times
    BACK TO TOP